<?xml version="1.0" encoding="UTF-8"?>
<p>Secondary endpoints of the study were: a) achievement of SVR24 defined as undetectable plasma HCV-RNA 24 weeks after the end of treatment; b) resource use: disaggregated data on drug acquisition cost and costs of clinical services used to treat patients and reimbursement costs based on the Medicare fee schedule and other published data were used to determine cost per SVR for both boceprevir and telaprevir.</p>
